Opinion
Video
The Potential Impact of Investigational Therapies
Author(s):
Innovative therapies for ovarian cancer, including engineered T cells and antibody-drug conjugates, show promise in improving patient outcomes.
Video content is prompted by the following: Future Potential of Novel Therapeutic Approaches
Key Discussion Points:
- TROP-2 ADCs
- Multiple TROP-2 ADCs in development, including sacituzumab govitecan and datopotamab deruxtecan
- Most require weekly or every-15-day dosing schedules vs 21-day dosing for other ADCs
- Clinical development decisions likely to be influenced by biomarker selection, toxicity profiles, and patient convenience factors
- Additional ADC Development
- Multiple targeted ADCs in clinical development (catherin-6, folate, claudin-6, B7H4)
- Next generation agents like IMGN-151 (biparatopic folate–targeted with different microtubule toxin)
- Selection criteria may shift toward safety and patient experience if efficacy appears similar
- Cellular Therapies
- Engineered T-cells showing more promise than CAR T in ovarian cancer
- CAR-NK cells potentially more promising than CAR T
- Manufacturing challenges include extended production time and patient selection issues
Notable Insights:
“CAR T, the limitation with ovary is that a lot of our proteins are intracellular proteins...but CAR-NK may be a completely different ballgame for us.”
“The challenge with [cellular therapies] is...you can’t leave people just sitting around for 2 months waiting for manufacture of cells who have kind of actively growing disease. It’s not ethical.”
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
